← Leaderboards
Maliha Zahid
Vivasc Therapeutics Inc.
$3,309,281
Attributed
$3,309,281
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $911.2K · FY2020–24$1M$750K$500K$250K$0
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$3,309,281 · 2
By mechanism
R01$2,981,992 · 1
R41$327,289 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Technology”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Leonard Freedman · Leidos Biomedical Research, Inc.$436,612,396
- Valerie Koch · University Corporation For Atmospheric Res$252,793,840
- Joel A Lipkin · Four Points Technology, Llc$178,737,225
- Lisa Garcia Bedolla · University Of California-Berkeley$175,927,128
Research focus
TechnologyAffectMortalityShortness Of BreathVectorPeptidesIn VivoMorbidity - Disease RateOrganPositioning AttributeTissuesUptakeCellsChronicHeartInjectionsLabelLungAmino AcidsCardiacApoptoticAirway ObstructionCell NucleusAffinity
Grant awards (7)
Targeting Underlying Pathophysiological Mechanisms to Develop Novel Therapies for Chronic Obstructive Lung Disease$608,962
R01 · FY2024 · HL · contact PI
Targeting Underlying Pathophysiological Mechanisms to Develop Novel Therapies for Chronic Obstructive Lung Disease$621,390
R01 · FY2023 · HL · contact PI
Targeting Underlying Pathophysiological Mechanisms to Develop Novel Therapies for Chronic Obstructive Lung Disease$583,879
R01 · FY2022 · HL · contact PI
Targeting Underlying Pathophysiological Mechanisms to Develop Novel Therapies for Chronic Obstructive Lung Disease$1
R01 · FY2022 · HL · contact PI
Targeting Underlying Pathophysiological Mechanisms to Develop Novel Therapies for Chronic Obstructive Lung Disease$583,880
R01 · FY2021 · HL · contact PI
Targeting Underlying Pathophysiological Mechanisms to Develop Novel Therapies for Chronic Obstructive Lung Disease$583,880
R01 · FY2020 · HL · contact PI
Targeted delivery of amiodarone to the heart for atrial fibrillation utilizing novel cardiac targeting peptides$327,289
R41 · FY2020 · HL · contact PI